**Supplementary Table 4. Network meta-analysis results for primary and secondary prophylaxis of variceal bleeding and all-cause mortality according to geographical region**

|  |  |  |
| --- | --- | --- |
| **Bleeding (primary + secondary prophylaxis)**  |  |  |
| *Asia* (10 studies) |  |  |
|  Carvedilol  1.49 (0.45, 4.99) Nadolol 0.49 (0.11, 1.68) 0.33 (0.07, 1.14)  | Propranolol  |   |
|  0.56 (0.16, 1.92) 0.38 (0.11, 1.23)  | 1.16 (0.57, 2.96)  | Placebo  |
| *Non-Asia* (19 studies) |  |  |
| Carvedilol 0.00 (0.00, 0.74)  | Nadolol  |   |   |
| 0.00 (0.00, 0.34)  | 0.46 (0.13, 1.45)  | Propranolol  |   |
| 0.00 (0.00, 0.15)  | **0.20 (0.06, 0.57)**  | **0.42 (0.27, 0.64)**  | Placebo  |
| **All-cause mortality**  |  |  |  |
| *Asia* (9 studies)Carvedilol0.76 (0.27, 1.93)  |  |  |  |
| Nadolol  |   |   |
| **0.32 (0.09, 0.94)**  | 0.42 (0.11, 1.41)  | Propranolol  |   |
| **0.28 (0.11, 0.65)**  | **0.38 (0.13, 0.98)**  | 0.90 (0.40, 2.14)  | Placebo  |
| *Non-Asia* (16 studies) |  |  |
| Carvedilol 0.52 (0.12, 2.13)  | Nadolol  |   |   |
| 0.39 (0.10, 1.27)  | 0.74 (0.33, 1.64)  | Propranolol  |   |
| **0.29 (0.08, 0.94)**  | 0.56 (0.26, 1.14)  | 0.75 (0.53, 1.05)  | Placebo  |

Data are presented as pooled relative risk (95% credible interval). Bold text indicates statistically significant value.